Goodrx is trading 5.6% up now at $3.87 after investors continued responding to August 5 second-quarter results and raised 2026 guidance.
- Revenue reached $200.4 million.
- Management cited 39% subscription growth and 76% Pharma Direct growth as key drivers of the improved outlook.
- Morgan Stanley raised its price target from $3 to $4 while maintaining an Equalweight rating.